Alpenglow Biosciences

Executive Summary

Alpenglow Biosciences provides an end-to-end 3D spatial biology platform that integrates proprietary open-top light-sheet microscopy, scalable data management, and AI-powered analytics. The platform transforms intact tissue samples into quantitative 3D datasets, enabling researchers in pharmaceutical, biotechnology, and academic settings to gain deeper insights into tissue microenvironments and disease mechanisms. By preserving tissue architecture and enabling high-resolution, whole-sample imaging, Alpenglow's technology addresses critical limitations of traditional 2D histology and standard 3D imaging approaches. The company's solution is designed to accelerate drug discovery, biomarker identification, and preclinical validation, positioning it as a key enabler in the growing spatial biology market. Founded in 2016 and based in Boulder, Colorado, Alpenglow is currently in the pre-clinical stage, focusing on research-use-only applications while building the foundation for future diagnostic use. The company's integrated platform reduces workflow complexity and analysis time, offering a competitive advantage over fragmented single-modality solutions. With increasing adoption of spatial biology in oncology, immunology, and neurology, Alpenglow is well-positioned to capture market share. Key near-term objectives include expanding commercial partnerships, refining AI algorithms, and raising capital to scale operations. The company’s technology has the potential to transform tissue analysis in both research and clinical settings, driving significant value for stakeholders.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top-10 pharmaceutical company for drug discovery applications60% success
• Q2 2026Launch of next-generation AI analytics module for automated 3D image analysis75% success
• Q4 2026Completion of Series A funding round to support commercial expansion50% success